Experimental and Molecular Medicine

Korean Society for Biochemistry and Molecular Biongy (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients

Cho, Kyung-Hyun;Shin, Dong-Gu;Baek, Suk-Hwan;Kim, Jae-Ryong

  • Published : 20090200
⟨ Previous Next ⟩

Abstract

Several parameters and risk factors were compared between Korean male myocardial infarction (MI) patients (n = 10) and angina pectoris (AP) patients (n = 17) to search unique biomarkers for myocardial infarction (MI) in lipoprotein level. Individual serum and lipoprotein fractions (VLDL, LDL, $HDL_2$, $HDL_3$) were isolated and analyzed by lipid and protein determination and enzyme assay. The MI group was found to have a 25 and 30% higher serum cholesterol and triacylglycerol (TG) level than the AP group, respectively, however, their body mass index (BMI), LDL-cholesterol (C), HDL-C, and glucose levels fell within the normal range. MI patients were found to have an approximately two-fold higher level of serum IL-6 and an 18% lower serum apoA-I level than that of the AP group. LDL and $HDL_2$ fraction of the MI group were more enriched with TG than those of AP group. The increased TG was correlated well with the increased level of apoC-III in the same fraction. Cholesteryl ester transfer protein (CETP) activity and protein level were greatly increased in MI patients in the LDL and $HDL_3$ fractions. MI patients showed more severely oxidized LDL fraction than patients in the AP group, as well as the weakest antioxidant ability of serum. Conclusively, MI patients were found to have unique serum and lipoprotein characteristics including increased IL-6 and TG in serum, with CETP and apoC-III in the LDL and HDL fractions, as well as severely impaired antioxidant ability of HDL.

Keywords

References

  1. Asia pacific cohort studies collaboration. Serum triglyceridesas a risk factor for cardiovascular diseases in the asia-pacificregion. Circulation 2004;110:2678-86 https://doi.org/10.1161/01.CIR.0000145615.33955.83
  2. Austin MA, Breslow JL, Hennekens CH, Buring JE, WillettWC, Krauss RM. Low-density lipoprotein subclass patternsand risk of myocardial infarction. J Am Med Assoc 1988;260:1917-21 https://doi.org/10.1001/jama.260.13.1917
  3. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, FolsomAR, Heiss G, Sharrett AR. Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk forIncident Coronary Heart Disease in Middle-Aged Men andWomen in the Atherosclerosis Risk in Communities (ARIC)Study. Circulation 2004;109:837-42 https://doi.org/10.1161/01.CIR.0000116763.91992.F1
  4. Benzie IF, Strain JJ. The ferric reducing ability of plasma(FRAP) as a measure of 'antioxidant power': the FRAPassay. Anal Biochem 1996;239:70-6 https://doi.org/10.1006/abio.1996.0292
  5. Boyd HF, Fell SCM, Flynn ST, Hickey DMB, Ife RJ, Leach CA,Macphee CH, Milliner KJ, Moores KE, Pinto IL, Porter RA,Rawlings DA, Smith SA, Stansfield IG, Tew DG, TheobaldCJ, Whittaker CM. N-1 substituted pyrimidin-4-ones: novel,orally active inhibitors of lipoprotein-associated phospholipaseA2. Bioorg Med Chem Lett 2000;10:2557-61 https://doi.org/10.1016/S0960-894X(00)00510-2
  6. Campos H, Genest JJ, Blijlevens E, McNamara JR, JennerJL, Ordovas JM, Wilson PWF, Shaefer EJ. Low densitylipoprotein particle size and coronary artery disease.Arterioscler Thromb 1992;12:187-95 https://doi.org/10.1161/01.ATV.12.2.187
  7. Cho KH, Lee JY, Choi MS, Cho JM, Lim JS, Park YB. A peptidefrom hog plasma that inhibits human cholesteryl estertransfer protein. Biochim Biophys Acta 1998;1391:133-44 https://doi.org/10.1016/S0005-2760(97)00197-5
  8. Cho KH, Park SH, Han JM, Kim HC, Choi YK, Choi I. ApoA-Imutants V156K and R173C promote anti-inflammatoryfunction and antioxidant activities. Eur J Clin Invest 2006;36:875-82 https://doi.org/10.1111/j.1365-2362.2006.01737.x
  9. Cho KH, Park JE, Kim YO, Choi I, Kim JJ, Kim JR. Thefunction, composition, and particle size of high-densitylipoprotein were severely impaired in an oliguric phase ofhemorrhagic fever with renal syndrome. Clin Biochem2008;41:56-64 https://doi.org/10.1016/j.clinbiochem.2007.10.007
  10. Eckerson HW, Wyte CM, La Du BN. The human serumparaoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-38
  11. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M,Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y,Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE.Elevated levels of oxidized low density lipoprotein show apositive relationship with the severity of acute coronarysyndromes. Circulation 2001;103:1955-60 https://doi.org/10.1161/01.CIR.103.15.1955
  12. Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM,Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN,Schaefer EJ. Famillial lipoprotein disorders in patients withpremature coronary artery disease. Circulation 1992;85:2025-33 https://doi.org/10.1161/01.CIR.85.6.2025
  13. Han JM, Jeong TS, Lee WS, Choi I, Cho KH. Structural andfunctional properties of V156K and A158E mutants ofapolipoprotein A-I in the lipid-free and lipid-bound states. JLipid Res 2005;46:589-96 https://doi.org/10.1194/jlr.M400468-JLR200
  14. Hartford M, Wiklund O, Hullten LM, Persson A, Karlsson T,Herlitz J, Caidahl K. C reactive protein, interleukin-6,secretory phospholipase A group IIA and intercellularadhesion molecule-1 in the prediction of late outcome eventsafter acute coronary syndromes. J Intern Med 2007;262:526-36 https://doi.org/10.1111/j.1365-2796.2007.01862.x
  15. Hokanson JE, Austin MA. Plasma triglyceride level is a riskfactor for cardiovascular disease independent of highdensitylipoprotein cholesterol level. J Cardiovasc Risk 1996;3:213-9 https://doi.org/10.1097/00043798-199604000-00014
  16. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS,Galvani M, Katus H. It's time for a change to a troponinstandard. Circulation 2000;102:1216-20 https://doi.org/10.1161/01.CIR.102.11.1216
  17. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL,Jameson JL. Harrison's 　Principles of Internal Medicine, 16thEd, McGraw-Hill, 2005, p.1444
  18. Libby P. Fat fuels the flame triglyceride-rich lipoproteins andarterial inflammation. Circulation 2007;100:299-3 https://doi.org/10.1161/01.RES.0000259393.89870.58
  19. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify proteindetermination in membrane and lipoprotein samples. AnalBiochem 1978;87:206-10 https://doi.org/10.1016/0003-2697(78)90586-9
  20. McBride PE. Triglycerides and risk for coronary heartdisease. J Am Med Assoc 2007;298:336-8 https://doi.org/10.1001/jama.298.3.336
  21. Meuwese MC, Stroes ESG, Hazen SL, Van Miert JN,Keivenhoven JA, Schaub RG, Wareham NJ, Luben R,Kastelein JJP, Khaw, KT, Boekholdt M. Serum myeloperoxidaselevels are associated with the future risk of coronaryartery disease in apparently healthy individuals. J Am CollCardiol 2007;50:159-65 https://doi.org/10.1016/j.jacc.2007.03.033
  22. Packard CJ, O''Reilly DSJ, Caslake MJ, McMahon AD, FordI, Cooney J, Macphee CH, Suckling KE, Krishna M, WilkinsonFE, Rumley A, Lowe GDO. Lipoprotein-associated phospholipaseA2 as an independent predictor of coronary heartdisease. West of Scotland Coronary Prevention StudyGroup. N Engl J Med 2000;343:1148-55 https://doi.org/10.1056/NEJM200010193431603
  23. Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, ApplegateWB. Emerging noninvasive biochemical measures to predictcardiovascular risk. Arch Intern Med 1999;159:237-45 https://doi.org/10.1001/archinte.159.3.237
  24. Rosamond W, Flegal K, Friday G, Furie K, Go A, GreenlundK. Heart disease and stroke statistics-2007 Update.Circulation 2007;115e:e69-e171 https://doi.org/10.1161/CIRCULATIONAHA.106.179918
  25. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B,Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, aolipoproteinB, CIII, and E, and risk of recurrent coronary events in thecholesterol and recurrent events trial. Circulation 2000;102:1886-92 https://doi.org/10.1161/01.CIR.102.16.1886
  26. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase:an inflammatory enzyme for generating dysfunctionalhigh density lipoprotein. Curr Opin Cardiol 2006;21:322-8 https://doi.org/10.1097/01.hco.0000231402.87232.aa
  27. Suzuki H, Kusuyama T, Sato R, Yokota Y, Tsunoda F, SatoT, Shoji M, Iso Y, Koba S, Katagiri T. Elevation of matrixmetalloproteinases and interleukin-6 in the culprit coronaryartery of myocardial infarction. Eur J Clin Invest 2008;38:166-73 https://doi.org/10.1111/j.1365-2362.2007.01919.x
  28. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS,Galvani M. Universal definition of myocardial infarction.Circulation 2007;116:2634-53 https://doi.org/10.1161/CIRCULATIONAHA.107.187397
  29. Tsimikas S, Willerson JT, Ridker, PM. C-Reactive protein andother emerging blood biomarkers to optimize risk stratificationof vulnerable patients. J Am Coll Cardiol 2006;47:C19-31 https://doi.org/10.1016/j.jacc.2005.10.066
  30. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V.C-reactive protein, interleukin-6 and tumor necrosis factoralpha as predictors of incident coronary and cardiovascularevents and total mortality. A population-based, prospectivestudy. Thromb Haemost 2006;95:511-8
  31. Walldius G, Jungner I. Is there a better marker of cardiovascularrisk than LDL cholesterol? Apolipoproteins Band A-I-new risk factors and targets for therapy. Nutr MetabCardiovasc Dis 2007;17:565-71 https://doi.org/10.1016/j.numecd.2007.02.010

Cited by

  1. Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL vol.27, pp.3, 2009, https://doi.org/10.1007/s10059-009-0037-8
  2. Monoacylglycerol (MAG)-Oleic Acid Has Stronger Antioxidant, Anti-Atherosclerotic, and Protein Glycation Inhibitory Activities than MAG-Palmitic Acid vol.13, pp.1, 2009, https://doi.org/10.1089/jmf.2009.1024
  3. Ethanol and Water Extract of Purple Sweet Potato Exhibits Anti-Atherosclerotic Activity and Inhibits Protein Glycation vol.13, pp.1, 2009, https://doi.org/10.1089/jmf.2009.1077
  4. Enhanced Delivery of Rapamycin by V156K-apoA-I High-Density Lipoprotein Inhibits Cellular Proatherogenic Effects and Senescence and Promotes Tissue Regeneration vol.66, pp.12, 2011, https://doi.org/10.1093/gerona/glr169
  5. Turmeric and Laurel Aqueous Extracts Exhibit In Vitro Anti-Atherosclerotic Activity and In Vivo Hypolipidemic Effects in a Zebrafish Model vol.14, pp.3, 2009, https://doi.org/10.1089/jmf.2009.1389
  6. IL-6 and TGF-α Costimulate Mesenchymal Stem Cell Vascular Endothelial Growth Factor Production by ERK-, JNK-, and PI3K-Mediated Mechanisms vol.35, pp.5, 2009, https://doi.org/10.1097/shk.0b013e31820b2fb9
  7. A zebrafish model for the rapid evaluation of pro-oxidative and inflammatory death by lipopolysaccharide, oxidized low-density lipoproteins, and glycated high-density lipoproteins vol.31, pp.6, 2009, https://doi.org/10.1016/j.fsi.2011.08.006
  8. Electronegative LDL: a useful biomarker of cardiovascular risk? vol.7, pp.3, 2009, https://doi.org/10.2217/clp.12.26
  9. Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk vol.222, pp.1, 2012, https://doi.org/10.1016/j.atherosclerosis.2012.02.024
  10. Modified High-Density Lipoproteins by Artificial Sweetener, Aspartame, and Saccharin, Showed Loss of Anti-atherosclerotic Activity and Toxicity in Zebrafish vol.15, pp.1, 2015, https://doi.org/10.1007/s12012-014-9273-z
  11. OXIDATIVE STRESS IN ACUTE CORONARY SYNDROME vol.4, pp.87, 2009, https://doi.org/10.14260/jemds/2015/2160
  12. Enhancement of High-Density Lipoprotein Cholesterol Functions by Encapsulation of Policosanol Exerts Anti-Senescence and Tissue Regeneration Effects Via Improvement of Anti-Glycation, Anti-Apoptosis, vol.19, pp.1, 2016, https://doi.org/10.1089/rej.2015.1712
  13. Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study vol.118, pp.1, 2009, https://doi.org/10.1161/circresaha.115.306223
  14. Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis vol.18, pp.None, 2009, https://doi.org/10.1186/s13075-016-1204-x
  15. Impaired Antioxidant Ability of HDL and More Oxidized LDL are associated with Male Patients with Atrial Fibrillation vol.5, pp.2, 2016, https://doi.org/10.12997/jla.2016.5.2.145
  16. Consumption of policosanol enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat in young and middle-aged subjects vol.39, pp.4, 2009, https://doi.org/10.3892/ijmm.2017.2907
  17. Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction vol.10, pp.1, 2017, https://doi.org/10.1161/circgenetics.116.001564
  18. Slim Body Weight Is Highly Associated With Enhanced Lipoprotein Functionality, Higher HDL-C, and Large HDL Particle Size in Young Women vol.9, pp.None, 2009, https://doi.org/10.3389/fendo.2018.00406
  19. Blood Pressure Lowering Effect of Cuban Policosanol is Accompanied by Improvement of Hepatic Inflammation, Lipoprotein Profile, and HDL Quality in Spontaneously Hypertensive Rats vol.23, pp.5, 2009, https://doi.org/10.3390/molecules23051080
  20. Cuban Sugar Cane Wax Acid and Policosanol Showed Similar Atheroprotective Effects with Inhibition of LDL Oxidation and Cholesteryl Ester Transfer via Enhancement of High-Density Lipoproteins Functiona vol.2019, pp.None, 2009, https://doi.org/10.1155/2019/8496409
  21. Epimedium koreanum Extract and Its Flavonoids Reduced Atherosclerotic Risk via Suppressing Modification of Human HDL vol.11, pp.5, 2019, https://doi.org/10.3390/nu11051110
  22. Anti-Atherosclerotic Effects of Fruits of Vitex rotundifolia and Their Isolated Compounds via Inhibition of Human LDL and HDL Oxidation vol.9, pp.11, 2009, https://doi.org/10.3390/biom9110727
  23. Cholesteryl Ester Transfer Protein Impairs Triglyceride Clearance via Androgen Receptor in Male Mice vol.56, pp.1, 2009, https://doi.org/10.1002/lipd.12271
  24. Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity vol.10, pp.2, 2021, https://doi.org/10.3390/antiox10020209